Glycine site agonists of the N‐methyl‐d‐aspartate receptor and Parkinson's disease: A hypothesis
- 20 February 2013
- journal article
- viewpoint
- Published by Wiley in Movement Disorders
- Vol. 28 (4) , 419-424
Abstract
Limitations of current pharmacological approaches to Parkinson's disease (PD) highlight the need for the development of nondopaminergic therapeutic strategies. The potential role of glutamatergic neurotransmission modulators, including those active at the N‐methyl‐D‐aspartate receptor (NMDAR), is presently under investigation. Most literature proposes the use of NMDAR antagonists based on neurodegenerative theories of NMDAR function. Nevertheless, NMDAR antagonism has proven disappointing in clinical trials and may be associated with serious adverse events. More recent theories indicate that NMDAR target selectivity may be a cardinal prerequisite for efficacy, with present efforts being devoted primarily to development of NMDAR‐NR2B subunit antagonists. We propose a novel hypothesis according to which NMDAR stimulation, accomplished through allosteric modulation via the glycine modulatory site, may be beneficial in late‐phase PD. This hypothesis stems from: (1) meta‐analysis of randomized controlled trials performed in schizophrenia, indicating that glycine site agonists (eg, glycine, D‐serine) alleviate antipsychotic‐induced parkinsonian symptoms; (2) clinical observations indicating that NMDAR hypofunction is associated with motor disturbances; (3) results of a preliminary D‐serine trial in PD; (4) data indicating glycine efficacy in a rat tardive dyskinesia model; and (5) no evidence of excitotoxic damage following chronic high‐dose glycine nutritional supplementation. This hypothesis is discussed in the context of glycine site agonist effects on intrasynaptic NMDAR subunits and striatal synaptic plasticity. © 2013 Movement Disorder SocietyKeywords
This publication has 42 references indexed in Scilit:
- Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitisThe Lancet Neurology, 2011
- High dose D-serine in the treatment of schizophreniaSchizophrenia Research, 2010
- Feedback inactivation of D-serine synthesis by NMDA receptor-elicited translocation of serine racemase to the membraneProceedings of the National Academy of Sciences, 2009
- Nitric oxide S -nitrosylates serine racemase, mediating feedback inhibition of d -serine formationProceedings of the National Academy of Sciences, 2007
- N-methyl-D-aspartate Receptor Subtypes: Multiple Roles in Excitotoxicity and Neurological DiseaseThe Neuroscientist, 2005
- Glutamate Receptors and Parkinson???s DiseaseDrugs & Aging, 2003
- Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: Intrastriatal microinjection studies in the 6‐OHDA‐lesioned ratMovement Disorders, 2002
- Direct and indirect presynaptic control of dopamine release by excitatory amino acidsAmino Acids, 1998
- Ligand affinities at recombinant receptors depend on subunit compositionEuropean Journal of Pharmacology: Molecular Pharmacology, 1994
- A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTSActa Psychiatrica Scandinavica, 1970